Literature DB >> 31236332

Prostate specific membrane antigen (PSMA) expression in vena cava tumour thrombi of clear cell renal cell carcinoma suggests a role for PSMA-driven tumour neoangiogenesis.

Giuliano Morgantetti1, Keng Lim Ng2,3, Hemamali Samaratunga4, Handoo Rhee3, Glenda C Gobe2, Simon T Wood3.   

Abstract

BACKGROUND: Clear cell renal cell carcinoma (ccRCC) is a malignant renal neoplasm with a peculiar propensity to propagate as a contiguous tumor extension via the renal vein and inferior vena cava, occasionally reaching the right atrium. This intravascular tumor extension, often referred to as a tumor thrombus, represents the active growing front of the cancer. Prostate specific membrane antigen (PSMA), a glycoprotein that is extensively used in prostate cancer diagnostics, is a useful vascular marker for a variety of solid tumors. It is expressed in renal carcinomas. The aim of the current investigation was to analyse and compare the expression of PSMA at the growing front of the vena cava tumor extension with that found in the primary renal lesion.
METHODS: Immunohistochemical (IHC) analysis of PSMA and CD34 was performed on archived paraffin embedded vena cava tumour thrombus tissue and matching renal tumours. These specimens were collected from radical nephrectomies of 10 patients with vena cava invasive (pT3b) ccRCC in a large tertiary hospital in Australia. Quantitative and qualitative morphometric analysis of PSMA IHC expression was performed with Aperio ImageScope morphometry using intensity and positive pixel counts of CD34 and PSMA from the IVC tumour slides and the corresponding renal tumour mass.
RESULTS: PSMA and CD34 immunostaining were noted in the neovasculature of IVC tumour and renal tumour tissue. There was a higher PSMA/CD34 positive pixel count ratio noted in IVC tumour tissue when compared to renal tumour tissue. PSMA showed consistently increased expression in vena cava tumour, in comparison with the renal tumour mass.
CONCLUSIONS: Intravascular venous tumour extension expresses PSMA more intensely compared to intrarenal tumour tissue neovasculature. Our data suggest a possible mechanism for PSMA in neoangiogenesis and local progression of ccRCC and therefore its usefulness as a biomarker of neoangiogenesis for future diagnostic and therapeutic advancements.

Entities:  

Keywords:  Prostate specific membrane antigen (PSMA); neoangiogenesis; renal cell carcinoma; tumour thrombi

Year:  2019        PMID: 31236332      PMCID: PMC6559938          DOI: 10.21037/tau.2019.04.10

Source DB:  PubMed          Journal:  Transl Androl Urol        ISSN: 2223-4683


  28 in total

1.  Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction.

Authors:  Rebecca E Conway; Nenad Petrovic; Zhong Li; Warren Heston; Dianqing Wu; Linda H Shapiro
Journal:  Mol Cell Biol       Date:  2006-07       Impact factor: 4.272

2.  Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen.

Authors:  S S Chang; V E Reuter; W D Heston; P B Gaudin
Journal:  Urology       Date:  2001-04       Impact factor: 2.649

3.  Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.

Authors:  S S Chang; V E Reuter; W D Heston; N H Bander; L S Grauer; P B Gaudin
Journal:  Cancer Res       Date:  1999-07-01       Impact factor: 12.701

4.  Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues.

Authors:  G L Wright; C Haley; M L Beckett; P F Schellhammer
Journal:  Urol Oncol       Date:  1995 Jan-Feb       Impact factor: 3.498

5.  The human hematopoietic progenitor cell antigen (CD34) in vascular neoplasia.

Authors:  S T Traweek; P L Kandalaft; P Mehta; H Battifora
Journal:  Am J Clin Pathol       Date:  1991-07       Impact factor: 2.493

6.  Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms.

Authors:  Angelo Baccala; Linda Sercia; Jianbo Li; Warren Heston; Ming Zhou
Journal:  Urology       Date:  2007-08       Impact factor: 2.649

Review 7.  Evaluation of microvascular density in tumors: pro and contra.

Authors:  Beatrice Nico; Vincenzo Benagiano; Domenica Mangieri; Nicola Maruotti; Angelo Vacca; Domenico Ribatti
Journal:  Histol Histopathol       Date:  2008-05       Impact factor: 2.303

8.  Long-term experience with management of renal cell carcinoma involving the inferior vena cava.

Authors:  Nabil K Bissada; Hossam H Yakout; Aga Babanouri; Tarek Elsalamony; Wahib Fahmy; Moustafa Gunham; Gerald W Hull; Uzair B Chaudhary
Journal:  Urology       Date:  2003-01       Impact factor: 2.649

Review 9.  Targeted treatment of prostate cancer.

Authors:  Xinning Wang; Lihong Yin; Pravin Rao; Robert Stein; Kelley M Harsch; Zhenghong Lee; Warren D W Heston
Journal:  J Cell Biochem       Date:  2007-10-15       Impact factor: 4.429

10.  Chapter 14. Measuring intratumoral microvessel density.

Authors:  Noel Weidner
Journal:  Methods Enzymol       Date:  2008       Impact factor: 1.600

View more
  3 in total

1.  PSMA PET-CT Imaging Predicts Treatment Progression in Men with Biochemically Recurrent Prostate Cancer-A Prospective Study of Men with 3 Year Follow Up.

Authors:  Sean Ong; Claire Pascoe; Brian D Kelly; Zita Ballok; David Webb; Damien Bolton; Declan Murphy; Shomik Sengupta; Patrick Bowden; Nathan Lawrentschuk
Journal:  Cancers (Basel)       Date:  2022-05-31       Impact factor: 6.575

2.  Expression of VEGF, CD73 and their relationship with clinical pathology, microvessel density, and prognosis in renal cell carcinoma.

Authors:  Xuefeng Mei; Jia Shu; Ruizhen Huang; Xin Chu; Ying Tian
Journal:  Transl Androl Urol       Date:  2020-06

3.  Expression of Prostate-specific Membrane Antigen (PSMA) in Papillary Renal Cell Carcinoma - Overview and Report on a Large Multicenter Cohort.

Authors:  Stefanie Zschäbitz; Franziska Erlmeier; Christine Stöhr; Edwin Herrmann; Iris Polifka; Abbas Agaimy; Lutz Trojan; Philipp Ströbel; Frank Becker; Christian Wülfing; Peter Barth; Michael Stöckle; Michael Staehler; Christian Stief; Axel Haferkamp; Markus Hohenfellner; Stephan Macher-Göppinger; Bernd Wullich; Joachim Noldus; Walburgis Brenner; Frederik C Roos; Bernhard Walter; Wolfgang Otto; Maximilian Burger; Andres Jan Schrader; Yvonne Mondorf; Arndt Hartmann; Philipp Ivanyi; Sandra Steffens
Journal:  J Cancer       Date:  2022-03-14       Impact factor: 4.207

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.